Document |
Document Title |
WO/2020/175392A1 |
A compound which has a molecular weight of 3,000 or less, while having a partial structure that is represented by formula (X). (In formula (X), ring W1 represents a ring structure that does not have aromaticity, while having at least one...
|
WO/2020/175393A1 |
A compound represented by general formula (I). [In formula (I), R3, R4, and R5 each independently represent an electron-attracting group. R1, R2, R6, and R7 each independently represent a hydrogen atom, a heterocyclic group, a halogen at...
|
WO/2020/161632A1 |
The present application provides novel polymorphic forms of siponimod, their processes, their use in purification of other crystalline polymorphic forms of siponimod, and pharmaceutical compositions containing them. The present applicati...
|
WO/2020/156359A1 |
Disclosed in the present invention are a quaternary ammonium salt compound and a preparation method therefor and a use thereof, relating to the field of medicinal chemistry. Disclosed in the present invention is the compound shown in for...
|
WO/2020/159824A1 |
Provided herein are pharmaceutical compositions comprising compounds that inhibit Factor XIa or kallikrein and methods of use thereof.
|
WO/2020/154250A1 |
Disclosed is method for converting a beta-lactam antibiotic into a "masked" beta- lactam antibiotic to permit it to cross the waxy cuticle of a plant and then subsequently unmasking the beta-lactam and converting it into an active beta-l...
|
WO/2020/146568A1 |
A method for the synthesis of diazabicyclo[6.2.0]decane compounds is provided. The synthesis proceeds by stereoselective synthesis of a chiral lactone followed by azetidine formation via a series of chemoselective reactions. Bicyclizatio...
|
WO/2020/142742A1 |
Compounds and compositions for modulating fibroblast activation protein (FAP) are described. The compounds and compositions may find use as therapeutic agents for the treatment of diseases, including hyperproliferative diseases.
|
WO/2020/114477A1 |
The present invention relates to a compound represented by the formula (II), the pharmaceutically acceptable salt thereof, and the uses of the compound acting as an S1P1 agonist.
|
WO/2020/118041A1 |
The disclosure provides ionizable amine lipids and salts thereof (e.g., pharmaceutically acceptable salts thereof) useful for the delivery of biologically active agents, for example delivering biologically active agents to cells to prepa...
|
WO/2020/109434A1 |
The present invention relates to compounds of formula (I), to processes for producing the compounds, and to electronic devices containing at least one compound of formula (I).
|
WO/2020/103884A1 |
Amides that inhibit cellular necrosis and/or human receptor interacting protein 1 kinase (RIP1), including corresponding sulfonamides, and pharmaceutically acceptable salts, hydrates and stereoisomers thereof. The compounds are employed ...
|
WO/2020/104930A1 |
The present invention relates to an improved asymmetric synthesis of azaspiro or di- azaspiro compound (hereafter referred to as the compound 5, (5A) or (5N)) or their pharmaceutically acceptable salts and derivatives; through the format...
|
WO/2020/104822A1 |
The present invention relates to a compound of formula (Ia), or a pharmaceutically acceptable salt or hydrate thereof, wherein: the group X-Y is -NHSO2- or -SO2NH-; R1 is H or alkyl; R2 is selected from COOH and a tetrazolyl group; R3 is...
|
WO/2020/098710A1 |
Provided in the present application are a substituted bis-aryl amide compound and a preparation method and an application therefor, the substituted bis-aryl amide compound or a pharmaceutically acceptable salt thereof having the structur...
|
WO/2020/080979A1 |
This disclosure relates to new phthalimide and isoindolinone derivatives and other PFKFB3 inhibitors for use in the treatment of diseases. The invention further relates to pharmaceutical compositions containing such PFKFB3 inhibitors, me...
|
WO/2020/074489A1 |
The present invention relates to compounds of Formula (I), wherein R1, R2, R3, R4 and G are as defined herein. The invention further relates to herbicidal compositions which comprise a compound of Formula (I), to their use for controllin...
|
WO/2020/056553A1 |
The invention belongs to the field of organic chemistry, and particularly relates to a method for preparing a heterocyclic compound represented by formula I and salts thereof. Compared with the prior art, the invention avoids the use of ...
|
WO/2020/052647A1 |
Involved are a class of spiro-heterocyclic compounds which can act as lysine-specific demethylase 1 (LSD1) inhibitors, and the use of same in the preparation of drugs for treating LSD1-related diseases. Specifically involved are a compou...
|
WO/2020/047991A1 |
Use of an anti-acarid additive in daily chemical products. Diaryl lactam compounds have excellent anti-acarid effects, and can be used in applications such as anti-acarid body wash, anti-acarid facial cleaners and anti-acarid daily chemi...
|
WO/2020/047198A1 |
The present invention relates to processes and intermediates for preparing 3-(cyanomethyl)-3-(4-{[(IR,2S)-2- phenylcyclopropyl]amino}piperi din-l-yl)azeti dine-1-sulfonamide, and salts and solid forms thereof, which selectively modulate ...
|
WO/2020/039092A2 |
The present invention comprises novel aromatic molecules, which can be used in the treatment of pathological conditions, such as cancer, skin diseases, muscle disorders, and immune system-related disorders such as disorders of the haemat...
|
WO/2020/039088A2 |
The present invention comprises novel aromatic molecules, which can be used in the treatment of pathological conditions, such as cancer, skin diseases, muscle disorders, and immune system-related disorders such as disorders of the haemat...
|
WO/2020/041100A1 |
Disclosed herein are compounds of formula (I) which are inhibitors of an IDO enzyme: Also disclosed herein are uses of the compounds in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein...
|
WO/2020/041384A1 |
3-Phenyl-2-cyano-azetidine derivatives and methods are provided for the inhibition of the function of RNA guided endonucleases, including the identification and use of such inhibitors. Methods of identifying inhibitor compounds of RNA gu...
|
WO/2020/035464A1 |
The present invention relates to compounds of formula (I): wherein Q is selected from O or S; R1 and R3 are each independently hydrogen or an optionally substituted hydrocarbyl group, or R1 and R3 together with the nitrogen atom to which...
|
WO/2020/017569A1 |
The purpose of the present invention is to provide a novel T-type calcium channel blocker. A compound represented by general formula (I), a tautomer or stereoisomer of the compound, a pharmaceutically acceptable salt thereof or a solvate...
|
WO/2019/235553A1 |
The present invention addresses the problem of providing a compound that is useful as a therapeutic or prophylactic for diseases related to the immune system, particularly autoimmune diseases such as systemic lupus erythematosus (SLE) an...
|
WO/2019/231933A2 |
The present disclosure provides, inter alia, compounds with MASP-2 inhibitory activity, compositions of such compounds and methods of making and using such compounds.
|
WO/2019/226490A1 |
Provided is a compound of Formula (I), wherein the variable groups are defined herein.
|
WO/2019/217977A1 |
Disclosed herein are compounds represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof. Values for the variables in Structural Formula I are described herein. The compounds can be used to modulate (e.g, inhib...
|
WO/2019/204740A1 |
The present disclosure provides azetidine compounds of Formula I and their pharmaceutically acceptable salts, their compositions, and methods for their use in determining azetidine compound binding to proteins. The azetidine compounds ar...
|
WO/2019/200131A1 |
The present disclosure provides methods related to treating triple-negative breast cancer (TNBC) in a mammal by administering salvianolic acid B (or a salt or solvate thereof) to promote ceramide-mediated apoptosis. In one form, the cera...
|
WO/2019/183589A1 |
The present disclosure relates generally to eukaryotic initiation factor 2B modulators of formula A, or a pharmaceutically acceptable salt, stereoisomer, or mixture of stereoisomers thereof and methods of making and using thereof.
|
WO/2019/182924A1 |
Janus kinases (JAKs) inhibitors have Formula (I).
|
WO/2019/163917A1 |
Provided is a compound in which the balance of the agonist activity against the S1P5 receptor relative to the S1P1 receptor has been improved in order to develop a pharmaceutical useful for the treatment of S1P5-mediated diseases such as...
|
WO/2019/159168A1 |
The present invention provides cannabinoid derivatives, more specifically cannabidiol (CBD), desoxy-CBD, and desoxy-A9- tetrahydrocannabinol (desoxy-THC) derivatives, which are useful for neuroprotection, treating pain, or treating a dis...
|
WO/2019/154288A1 |
Disclosed in the present invention are a cationic compound, a preparation method therefor and a use thereof. Provided by the present invention is a compound represented by formula I having a novel structure, or a pharmaceutically accepta...
|
WO/2019/154287A1 |
Disclosed are a quaternary ammonium salt compound, a preparation method therefor and a use thereof. Provided is a novel structural compound as shown in formula Ⅰ, or a pharmaceutically acceptable salt thereof, or a stereoisomer thereof...
|
WO/2019/144094A1 |
Disclosed crystalline Siponimod fumaric acid, solid state forms (polymorphs) thereof, processes for preparation thereof and pharmaceutical compositions thereof.
|
WO/2019/101150A1 |
An HS-25 tablet, an HS-25 solid dispersion composition, a preparation method therefor and usage thereof. The HS-25 tablet is made by using HS-25 and excipients for wet granulation, drying, granulating and tablet pressing.
|
WO/2019/090088A1 |
Provided herein are compounds, compositions, and methods useful for modulating the integrated stress response (ISR) and for treating related diseases; disorders and conditions.
|
WO/2019/090090A1 |
Provided herein are compounds, compositions, and methods useful for the modulation of elF2B, for modulating the integrated stress response (ISR) and for treating related diseases; disorders and conditions.
|
WO/2019/068772A1 |
The present invention relates to compounds of formula (I): wherein Q is selected from O or S; R1 is a saturated or unsaturated hydrocarbyl group, wherein the hydrocarbyl group may be straight-chained or branched, or be or include cyclic ...
|
WO/2019/070672A1 |
Bromine induced lactamization of vinyl acetohydroxamates facilitated syntheses of monocyclic β-lactams suitable for incorporation of a thiomethyl and extended functionality at the C(4) position. Elaboration of the resulting substituted ...
|
WO/2019/062848A1 |
The present invention discloses an N-(substituted sulfonyl)benzamide derivative, a preparation method therefor, and a pharmaceutical use thereof. Specifically, the present invention discloses an N-(substituted sulfonyl)benzamide derivati...
|
WO/2019/064184A1 |
The present application provides process for preparation of siponimod, intermediates of siponimod, salts of siponimod, polymorphic forms and solid dispersions of siponimod and its salts thereof. The present application specifically provi...
|
WO/2019/056123A1 |
Pharmaceutical compositions comprising one or more cannabinoids and a pharmaceutically acceptable carrier are disclosed. The compositions are in a form suitable for topical administration, and are useful in the treatment of pain. The can...
|
WO/2019/055509A1 |
N-(6-(((2R,3S)-3,4-dihydroxy butan-2-yl)oxy)-2-((4-fluoro benzyl)thio)pyrimidin-4-yl)-3-methylazetidine-1-sulfonamide (compound 4), a known chemokine modulator, in combination with colchicine is useful in the treatment of diseases/condit...
|
WO/2019/045035A1 |
The present invention relates to biaryloxy derivatives which have blocking activities of voltage gated sodium channels as the TTX-S channels, and which are useful in the treatment or prevention of disorders and diseases in which voltage ...
|